Restless legs syndrome (RLS) and periodic leg movements (PLM)

The Parasomnias and Other Sleep-Related Movement Disorders

Volumn , Issue , 2010, Pages 213-228

  Allen, Richard P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84888003035     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511711947.024     Document Type: Chapter

References (75)

1. Willis T. De Animae Brutorum. London: Wells and Scott, 1672.
2. Wittmaack T. Pathologie und therapie der sensibilitat neurosen. Liepzig: Schafer, 1861.
3. Ekbom KA. Restless Legs. Stockholm: Ivar Haeggströms, 1945.
4. Ekbom KA. Restless legs syndrome. Neurology 1960; 10: 868-73.
5. Symonds CP. Nocturnal myoclonus. JNeurol Neurosurg Psychiatr 1953; 16: 166-71.
6. Lugaresi E, Coccagna G, Berti Ceroni G, Ambrosetto C. Restless legs syndrome and nocturnal myoclonus. In Gastaut H, Lugaresi E, Berti Ceroni G (Eds), The Abnormalites of Sleep in Man. Bologna: Aulo Gaggi Editore, 1968; 285-94.
7. Pennestri MH, Whittom S, Adam B, Petit D, Carrier J, Montplaisir J. PLMS and PLMW in healthy subjects as a function of age: Prevalence and interval distribution. Sleep 2006; 29: 1183-7.
8. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101-19.
9. Hening WA, Allen RP, Washburn M, Lesage S, Earley C. The four diagnostic criteria for the Restless Legs Syndrome are unable to exclude confounding conditions (“mimics”). Sleep Med 2009; 10: 976-81.
10. Manconi M, Govoni V, De Vito A, et al. Pregnancy as a risk factor for restless legs syndrome. Sleep Med2004; 5: 305-08.
11. Kavanagh D, Siddiqui S, Geddes CC. Restless legs syndrome in patients on dialysis. Am J Kidney Dis2004; 43: 763-71.
12. Winkelman J, Chertow G, Lagos L, et al. Restless legs syndrome is associated with reduced long term survival in patients with end-stage renal dialysis. APSS annual meeting; 1996; Washington, DC: APSS, 1996.
13. Akyol A, Kiylioglu N, Kadikoylu G, Bolaman AZ, Ozgel N. Iron deficiency anemia and restless legs syndrome: Is there an electrophysiological abnormality? Clin Neurol Neurosurg 2003; 106: 23-7.
14. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: The REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004; 5: 237-46.
15. Allen RP, La Buda MC, Becker P, Earley CJ. Family history study of the restless legs syndrome. Sleep Med2002; 3: S3-7.
16. Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med 2000; 1: 11-19.
17. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165: 1286-92.
18. Allen RP, Stillman P, Myers AJ. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in Western Europe: Prevalence and characteristics. Sleep Med. in press.
19. Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004; 164: 196-202.
20. Pantaleo NP, Hening WA, Allen RP, Earley CJ. Pregnancy accounts for most of the gender differences in prevalence of familial RLS. Sleeep Med in press.
21. Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther2004; 26: 925-35.
22. Siddiqui F, Strus J, Ming X, Lee IA, Chokroverty S, Walters AS. Rise of blood pressure with periodic limb movements in sleep and wakefulness. Clin Neurophysiol 2007; 118: 1923-30.
23. Winkelman JW, Shahar E, Sharief I, Gottlieb DJ. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 2008; 70: 35-42.
24. Saletu B, Gruber G, Saletu M, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 2000; 41: 181-9.
25. Xiong L, Jang K, Montplaisir J, et al. Canadian restless legs syndrome twin study. Neurology 2007; 68: 1631-3.
26. Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007; 357: 639-47.
27. Winkelmann J, Schormair B, Lichtner P, et al.Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007; 39: 1000-06.
28. Schormair B, Kemlink D, Roeske D, et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet2008; 40: 946-8.
29. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 1982; 39: 739.
30. Garcia-Borreguero D, Larrosa O, Granizo JJ, de la Llave Y, Hening WA. Circadian variation in neuroendocrine response to i-dopa in patients with restless legs syndrome. Sleep 2004; 27: 669-73.
31. Earley CJ, Hyland K, Allen RP. CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome. Mov Disord 2001; 16: 144-9.
32. Stiasny-Kolster K, Moller JC, Zschocke J, et al. Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients. Mov Disord 2004; 19: 192-6.
33. Earley CJ, Hyland K, Allen RP. Circadian changes in CSF dopaminergic measures in restless legs syndrome. Sleep Med 2006; 7: 263-8.
34. Allen RP, Connor JR, Hyland K, Earley CJ. Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. Sleep Med 2009; 10: 123-8.
35. Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP, Earley CJ. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003; 61: 304-09.
36. Pittock SJ, Parrett T, Adler CH, Parisi JE, Dickson DW, Ahlskog JE. Neuropathology of primary restless leg syndrome: Absence of specific tau-and alpha-synuclein pathology. Mov Disord 2004; 19: 695-9.
37. Connor JR, Wang X, Allen RP. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain in press.
38. Eisensehr I, Wetter TC, Linke R, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001; 57: 1307-09.
39. Tribl GG, Asenbaum S, Happe S, Bonelli RM, Zeitlhofer J, Auff E. Normal striatal D2 receptor binding in idiopathic restless legs syndrome with periodic leg movements in sleep. Nucl Med Commun2004; 25: 55-60.
40. Michaud M, Soucy JP, Chabli A, Lavigne G, Montplaisir J. SPECT imaging of striatal pre-and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002; 249: 164-70.
41. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999; 52: 932-7.
42. Cervenka S, Palhagen SE, Comley RA, et al. Support for dopaminergic hypoactivity in restless legs syndrome: A PET study on D2-receptor binding. Brain2006; 129: 2017-28.
43. Ondo WG, He Y, Rajasekaran S, Le WD. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: A possible model for restless legs syndrome. Mov Disord 2000; 15: 154-8.
44. Earley C, Allen RP, Connor JR, Ferrucci L, Troncoso J. The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal. Sleep Med in press.
45. Happe S, Tings T, Schettler V, Canelo M, Paulus W, Trenkwalder C. Low-density lipoprotein apheresis and restless legs syndrome. Sleep 2003; 26: A335-6.
46. Earley CJ, Heckler D, Horska A, Barker PB, Allen RP. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 2004; 5: 231-5.
47. Allen RP, Butcher A, Du W. Double-blind, placebo-controlled multi-center evaluation of restless legs syndrome (RLS) treatment with 1,000 mg of IV iron (ferric carboxymaltose -FCM). Sleep 2009; in press.
48. Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001; 56: 263-5.
49. Earley CJ, Barker PB, Horska A, Allen RP. MRI-determined regional brain iron concentrations in early-and late-onset restless legs syndrome. Sleep Med2006; 7: 459-61.
50. Schmidauer C, Sojer M, Seppi K, et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol 2005; 58: 630-4.
51. Godau J, Schweitzer KJ, Liepelt I, Gerloff C, Berg D. Substantia nigra hypoechogenicity: Definition and findings in restless legs syndrome. Mov Disord 2007; 22: 187-92.
52. Godau J, Wevers AK, Gaenslen A, et al. Sonographic abnormalities of brainstem structures in restless legs syndrome. Sleep Med 2008; 9: 782-9.
53. Godau J, Klose U, Di Santo A, Schweitzer K, Berg D. Multiregional brain iron deficiency in restless legs syndrome. Mov Disord 2008; 23: 1184-7.
54. Connor JR, Wang XS, Patton SM, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 2004; 62: 1563-7.
55. Chen Q, Beard JL, Jones BC. Abnormal rat brain monoamine metabolism in iron deficiency anemia. J Nutritional Biochem 1995; 6: 486-93.
56. Erikson KM, Jones BC, Hess EJ, Zhang Q, Beard JL. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain. Pharmacol Biochem Behav 2001; 69: 409-18.
57. Wang J, O’Reilly B, Venkataraman R, Mysliwiec V, Mysliwiec A. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study. Sleep Med 2009; 10: 973-5.
58. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: Results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry2004; 75: 92-7.
59. Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al.Efficacy of pramipexole in restless legs syndrome: A six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2007; 22: 213-9.
60. Oertel WH, Benes H, Garcia-Borreguero D, et al.Efficacy of rotigotine transdermal system in severe restless legs syndrome: A randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008; 9: 228-39.
61. Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: A randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008 Jul; 7: 595-604.
62. Lang AE, Hobson DE, Martin W, Rivest J. Excessive daytime sleepiness and sudden onset sleep in Parkinson’s disease: A survey from 18 Canadian movement disorders clinics. Neurology 2001; a: S40.001.
63. Bassetti C, Clavadetscher S, Gugger M, Hess CW. Pergolide-associated ‘sleep attacks’ in a patient with restless legs syndrome. Sleep Med 2002; 3: 275-7.
64. Quickfall J, Suchowersky O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord 2007; 13: 535-6.
65. Ondo WG, Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord 2008; 14: 28-32.
66. Vetrugno R, La Morgia C, D’Angelo R, et al.Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord 2007; 22: 424-7.
67. Earley CJ, Allen RP. Restless legs syndrome augmentation associated with tramadol. Sleep Med2006; 7: 592-3.
68. Ondo WG. Methadone for refractory restless legs syndrome. Mov Disord 2005; 20: 345-8.
69. Lundvall O, Abom PE, Holm R. Carbamazepine in restless legs. A controlled pilot study. Eur J Clin Pharmacol 1983; 25: 323-4.
70. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: A double-blind, cross-over study. Neurology 2002; 59: 1573-9.
71. Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009; 72: 439-46.
72. Sommer M, Bachmann CG, Liebetanz KM, Schindehutte J, Tings T, Paulus W. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand 2007; 115: 347-50.
73. von Spiczak S, Whone AL, Hammers A, et al. The role of opioids in restless legs syndrome: An [11C]diprenorphine PET study. Brain 2005; 128: 906-17.
74. Walters AS, Winkelmann J, Trenkwalder C, et al.Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001; 16: 1105-09.
75. Earley CJ, Heckler D, Allen RP. Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep Med 2005; 6: 301-05.